Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Rituximab-containing chemotherapy regimens constitute standard first-line therapy for mantle cell lymphoma (MCL). Since June 2013, 190 patients ≥18 years of age with MCL in British Columbia have been treated with bendamustine and rituximab (BR). The overall response rate to BR was 88% (54% complete...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Villa, Diego, Sehn, Laurie H., Savage, Kerry J., Toze, Cynthia L., Song, Kevin, den Brok, Wendie D., Freeman, Ciara L., Scott, David W., Gerrie, Alina S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Lymphoid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7422137/
https://ncbi.nlm.nih.gov/pubmed/32735654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002068
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia